Cilostazol: An "intermittent claudication" remedy for the management of third-degree AV block

Chest

Volumn 123, Issue 4, 2003, Pages 979-982

  Madias, John E ^a,b  

^a ELMHURST HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; AMRINONE; ATRIAL NATRIURETIC FACTOR; ATROPINE; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CILOSTAZOL; CLOPIDOGREL; ISOPRENALINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; XANTHINE DERIVATIVE;

ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR CONDUCTION; DISEASE SEVERITY; DRUG EFFECT; EDITORIAL; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART RATE; HEMODYNAMICS; HUMAN; INTERMITTENT CLAUDICATION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 0037388986     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.4.979     Document Type: Editorial

References (32)

1. Gregoratos G, Cheitlin MD, Freedman RA, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and anti-arrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998; 31:1175-1209
2. Braunwald E, Zipes D, Libby P, eds. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia, PA: W.B. Saunders, 2001; 700-815
3. Furman S, Robinson G. The use of an intracardiac pacemaker in the correction of total heart block. Surg Forum 1958; 9:245-248
4. Zoll PM, Zoll RH, Falk RH, et al. External noninvasive temporary cardiac pacing: clinical trials. Circulation 1985; 71:937-944
5. Francis GS. Insertion of a temporary transvenous ventricular pacemaker competence statement: clinical competence in insertion of a temporary transvenous ventricular pacemaker. ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll Cardiol 1994; 23:1254-1257
6. Hynes JK, Holmes DR, Harrison CE. Five-year experience with temporary pacemaker therapy in the coronary care unit. Mayo Clin Proc 1983; 58:122-126
7. Vardas PE, Travill CM, Williams TDM, et al. Effects of dual chamber pacing on raised plasma atrial natriuretic peptide concentrations in complete atrioventricular block. BMJ 1988; 296:94
8. Baratto MT, Berti S, Clerico A, et al. Atrial natriuretic peptide during different pacing modes in a comparison with hemodynamic changes. Pacing Clin Electrophysiol 1990; 13:432-442
9. La Villa G, Padeletti L, Lazzeri C, et al. Plasma levels of natriuretic peptides during ventricular pacing with a dual chamber pacemaker. Pacing Clin Electrophysiol 1994; 17:953-958
10. Davidson NC, Naas AA, Hanson JK, et al. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 15:823-831
11. Alboni P, Ratto B, Scarfo S, et al. Dromotropic effects of oral theophylline in patients with atrial fibrillation and slow ventricular response. Eur Heart J 1991; 12:630-634
12. Packer M, Carver JR, Chesebro JH, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991; 325:1468-1475
13. Piwonka RW, Healey JF, Canniff PC, et al. Electrophysiological actions of amrinone in dogs with cardiac lesions. J Cardiovasc Pharmacol 1983; 5:1052-1057
14. Naccarelli GV, Gray EL, Dougherty AH, et al. Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am J Cardiol 1984; 54:600-604
15. Naccarelli GV, Goldstein RA. Electrophysiology of phosphodiesterase inhibitors. Am J Cardiol 1989; 63:35A-40A
16. Goldstein RA, Geraci SA, Gray EL, et al. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 1986; 57:624-628
17. Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardiovasc Drug Rev 1993; 11:451-465
18. Shintani S, Watanabe K, Kawamura K, et al. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: effect on the peripheral organs. Arzneimittelforschung 1985; 35:1163-1172
19. Uchikawa T, Murakami T, Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 1992; 42:322-324
20. Liu Y, Fong M, Cone J, et al. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2000; 36:351-360
21. Reilly MP, Mohler ER III. Cilostazol: treatment of intermittent claudication. Ann Pharmacol 2001; 35:48-56
22. Cariski AT, Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Pract 2001; 119(Suppl):11-18
23. Tanaka T, Muneyuki T, Oka Y, et al. Effects of long-term administration on coronary flow velocity and coronary flow reserve. J Cardiol 1999; 34:183-188
24. Tsusui M, Shimokawa H, Higuchi S, et al. Effect of cilostazol, a novel anti-platetet drug, on restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J 1996: 60:207-215
25. Yoshitomi Y, Kojima S, Sugi T, et al. Antiplatelet treatment with cilostazol after stent implantation. Heart 1998; 80:393-396
26. Park SW, Lee CW, Kim HS, et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999; 84:511-514
27. Niki T, Mori H. Phase I study of cilostazol: safety evaluation at increasing single doses in healthy volunteers. Arzneimittelforschung 1985; 35:1173-1185
28. Suri A, Forbes WP, Bramer SL. Pharmacokinetics of multiple-dose cilostazol in middle-age and elderly men and women. J Clin Pharmacol 1998; 38:144-150
29. Atarashi H, Endoh Y, Saitoh H, et al. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J Cardiovasc Pharmacol 1998; 31:534-539
30. Yamashita S, Miyagawa K, Inagaki T, et al. Cilostazol increased heart rate with improvement of activity of daily living in an elderly patient with sick sinus syndrome. Nippon Ronen Igakkai Zasshi 1999; 36:561-564
31. Toyonaga S, Nakatsu T, Murakami T, et al. Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia J Cardiovasc Pharmacol 2000; 5:183-191
32. Kishida M, Watanabe K, Tsuruoka T. Effects of cilostazol in patients with bradycardiac atrial fibrillation. J Cardiol 2001; 37:27-33